Alex Friedlaender

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 132 citations · Full text

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Solène De Talhouet, Julien Péron, Aurélie Vuilleumier et al. · Scientific Reports · 2020 · 122 citations · Full text

Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists

Mauro Frigeri, Philippe Meyer, Raphaël Giraud et al. · Canadian Journal of Cardiology · 2017 · 96 citations

New Challenge, Heart Failure, Autoimmune Disease +8

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 95 citations · Full text

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6